Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?Zacks Investment Research • 04/21/25
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold ForeverThe Motley Fool • 04/17/25
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and NovartisZacks Investment Research • 04/14/25
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff ThreatZacks Investment Research • 04/11/25
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma TariffsInvestopedia • 04/10/25
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threatsReuters • 04/10/25
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkbackCNBC • 04/10/25
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play OutSeeking Alpha • 04/09/25
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug ImportsInvestors Business Daily • 04/09/25
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug ApprovalInvestors Business Daily • 04/03/25
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)PRNewsWire • 04/03/25
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of NovartisGlobeNewsWire • 03/31/25
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancerGlobeNewsWire • 03/28/25